Back to Search
ALAN VENOOK, MD
MD
Medical Oncology Physician
NPI: 1487618831Individual
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
G44869(CA)
Hematology (Internal Medicine) Physician
Internal Medicine — Hematology
Code: 207RH0000X
G44869(CA)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
G44869(CA)
Research & Publications (20)
Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma.
PMID 17553204·Clin Colorectal Cancer·2007
3-trial
Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma.
PMID 15880563·Cancer·2005
6-review
Critical evaluation of current treatments in metastatic colorectal cancer.
PMID 15821245·Oncologist·2005
6-review
Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
PMID 16356309·Clin Colorectal Cancer·2005
3-trial
Key research issues in the management of hepatocellular carcinoma.
PMID 15309518·Cancer Chemother Pharmacol·2004
8-other
Colorectal metastases confined to the liver: a unique opportunity?
PMID 14523793·Semin Oncol·2003
6-review
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
PMID 14630685·Ann Oncol·2003
3-trial
Induction therapy in patients with metastatic colorectal cancer.
PMID 14508724·Semin Oncol·2003
6-review
Therapeutic approaches to metastasis confined to the liver.
PMID 11177742·Curr Oncol Rep·2001
6-review
Regional strategies for managing hepatocellular carcinoma.
PMID 10742963·Oncology (Williston Park)·2000
6-review
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
PMID 10894879·J Clin Oncol·2000
3-trial
Design issues in dose-finding Phase I trials for combinations of two agents.
PMID 19384692·J Biopharm Stat·2009
8-other
NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
PMID 19406039·J Natl Compr Canc Netw·2009
6-review
A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher.
PMID 19461906·Gastrointest Cancer Res·2009
8-other
Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
PMID 18849011·Clin Gastroenterol Hepatol·2009
8-other
Drug development in advanced colorectal cancer: challenges and opportunities.
PMID 19336009·Curr Oncol Rep·2009
6-review
Responding to the rising incidence of hepatocellular carcinoma with targeted therapy.
PMID 19259302·Gastrointest Cancer Res·2008
8-other
Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
PMID 19029408·J Clin Oncol·2008
8-other
NCCN Task Force Report: mTOR inhibition in solid tumors.
PMID 18926092·J Natl Compr Canc Netw·2008
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1600 DIVISADERO STREET
SAN FRANCISCO, CA 94143 - Phone
- (415) 353-9888
Quick Facts
- NPI
- 1487618831
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile